Solitary fibrous tumor with IGF-II-induced non-islet cell tumor hypoglycemia: a case report and molecular characterization by next-generation sequencing.
IGF-II
RNA sequencing
non-islet cell tumor hypoglycemia
solitary fibrous tumor
whole genome sequencing
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
03
2023
accepted:
19
06
2023
medline:
20
7
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
Non-islet cell tumor-induced hypoglycemia (NICTH) is a rare, life-threatening medical condition caused by excessive insulin-like growth factor II (IGF-II) secretion from tumors of most commonly mesenchymal origin. Using next-generation sequencing, we have characterized the genome and transcriptome of the resected IGF-II-secreting solitary fibrous tumor from a patient with severe hypoglycemia accompanied by hypoglycemia unawareness. A 69-year-old male patient presenting with abdominal discomfort was examined using computer tomography, revealing a large lesion at the lesser pelvis extending above the umbilicus. As no bone and lymph node metastases were detected, the patient was scheduled for laparotomy. Before surgery, the patient presented with symptoms of severe hypoglycemia. Suppressed C-peptide levels and subsequent hypokalemia indicated a possible case of NICTH. The patient was treated with methylprednisolone (8 mg) to assess hypoglycemia. After the surgery, mild hypoglycemia was present for the postoperative period, and no radiological recurrences were observed 3 and 12 months after discharge. Histopathological examination results were consistent with the diagnosis of malignant solitary fibrous tumor (SFT). Overexpression of IGF-II was confirmed by both immunohistochemistry and RNA sequencing. Further NGS analysis revealed an SFT characteristic alteration- While the
Sections du résumé
Background
UNASSIGNED
Non-islet cell tumor-induced hypoglycemia (NICTH) is a rare, life-threatening medical condition caused by excessive insulin-like growth factor II (IGF-II) secretion from tumors of most commonly mesenchymal origin. Using next-generation sequencing, we have characterized the genome and transcriptome of the resected IGF-II-secreting solitary fibrous tumor from a patient with severe hypoglycemia accompanied by hypoglycemia unawareness.
Case presentation
UNASSIGNED
A 69-year-old male patient presenting with abdominal discomfort was examined using computer tomography, revealing a large lesion at the lesser pelvis extending above the umbilicus. As no bone and lymph node metastases were detected, the patient was scheduled for laparotomy. Before surgery, the patient presented with symptoms of severe hypoglycemia. Suppressed C-peptide levels and subsequent hypokalemia indicated a possible case of NICTH. The patient was treated with methylprednisolone (8 mg) to assess hypoglycemia. After the surgery, mild hypoglycemia was present for the postoperative period, and no radiological recurrences were observed 3 and 12 months after discharge. Histopathological examination results were consistent with the diagnosis of malignant solitary fibrous tumor (SFT). Overexpression of IGF-II was confirmed by both immunohistochemistry and RNA sequencing. Further NGS analysis revealed an SFT characteristic alteration-
Conclusion
UNASSIGNED
While the
Identifiants
pubmed: 37469410
doi: 10.3389/fonc.2023.1188579
pmc: PMC10352493
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1188579Informations de copyright
Copyright © 2023 Niedra, Konrade, Peculis, Isajevs, Saksis, Skapars, Sivins, Daukste, Mezaka and Rovite.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pathology. 2021 Oct;53(6):713-719
pubmed: 33745702
Clin Endocrinol (Oxf). 2014 Jun;80(6):773-81
pubmed: 24593700
RNA Biol. 2016;13(4):466-72
pubmed: 26853560
Cells. 2020 Oct 12;9(10):
pubmed: 33053840
Biochem Biophys Res Commun. 2020 May 28;526(2):287-292
pubmed: 32216968
Endocrinol Metab Clin North Am. 1999 Sep;28(3):495-500, v-vi
pubmed: 10500927
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Mod Pathol. 2016 Dec;29(12):1511-1522
pubmed: 27562490
Front Endocrinol (Lausanne). 2019 May 15;10:316
pubmed: 31156561
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Case Rep Endocrinol. 2013;2013:308086
pubmed: 24194988
Front Endocrinol (Lausanne). 2018 Apr 09;9:117
pubmed: 29686648
Cell Rep Methods. 2023 May 08;3(5):100467
pubmed: 37323575
Med Oncol. 2003;20(4):403-8
pubmed: 14716039
Cancer Res. 1999 Dec 1;59(23):5989-94
pubmed: 10606246
Nat Commun. 2022 Jul 30;13(1):4434
pubmed: 35907924
Nature. 2012 Aug 30;488(7413):660-4
pubmed: 22895193
BMC Endocr Disord. 2020 May 11;20(1):60
pubmed: 32393233
Diagn Pathol. 2021 Apr 20;16(1):32
pubmed: 33879215
Am J Pathol. 2021 Apr;191(4):602-617
pubmed: 33497701
Adv Anat Pathol. 2021 Jan;28(1):44-58
pubmed: 32960834
BMC Endocr Disord. 2022 Oct 27;22(1):262
pubmed: 36303203
Bioinformatics. 2012 Dec 15;28(24):3211-7
pubmed: 23071270
F1000Res. 2020 Jan 29;9:63
pubmed: 32269765
Hum Pathol. 2015 Mar;46(3):347-56
pubmed: 25582503
Pathol Int. 2020 Mar;70(3):129-139
pubmed: 31904167
Haematologica. 2021 Jun 01;106(6):1545-1558
pubmed: 32414855
Mod Pathol. 2009 Jul;22(7):914-21
pubmed: 19407853
J Epidemiol. 2018 Aug 5;28(8):353-360
pubmed: 29576601
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Genome Biol. 2014;15(12):550
pubmed: 25516281
Am J Surg Pathol. 2012 Aug;36(8):1202-15
pubmed: 22613995
J Mol Med (Berl). 2019 Oct;97(10):1413-1425
pubmed: 31321477
Trends Cancer. 2021 Feb;7(2):98-111
pubmed: 33109489
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Sci Rep. 2017 Jan 16;7:40488
pubmed: 28091594
Mod Pathol. 2017 Oct;30(10):1433-1442
pubmed: 28731041
Mod Pathol. 2015 Oct;28(10):1324-35
pubmed: 26226844
Onco Targets Ther. 2018 Aug 28;11:5227-5238
pubmed: 30214228
Cancers (Basel). 2021 Jun 10;13(12):
pubmed: 34200924
J Hypertens Suppl. 1992 Apr;10(1):S5-10
pubmed: 1619503
Histopathology. 2018 Nov;73(5):843-851
pubmed: 29985536
Mol Metab. 2021 Oct;52:101245
pubmed: 33962049
J Pathol. 2010 Jul;221(3):300-7
pubmed: 20527023
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 34137435
J Clin Endocrinol Metab. 2014 Mar;99(3):713-22
pubmed: 24423303
Nat Biotechnol. 2017 Apr 11;35(4):316-319
pubmed: 28398311
Endocr Rev. 2013 Dec;34(6):798-826
pubmed: 23671155
Front Oncol. 2021 Dec 22;11:736969
pubmed: 35004271
PLoS One. 2013 May 29;8(5):e64497
pubmed: 23734203